New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 26, 2020 - Chiasma announced the FDA approval of Mycapssa (octreotide), for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Download PDF
Return to publications
